Development and Evaluation of Clinical Pharmacy Services in Respiratory Diseases

NCT05564156 | Completed

• 1 other identifier: Pharm. Role Resp. Disease Ward
• Study Type: interventional
• Target: 168
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical pharmacists in the healthcare system are experts in therapeutics and the use of drugs. They routinely provide medication reviews and recommendations to patients and healthcare professionals. Clinical pharmacists are a scientifically valid source of information and give advice on the safe and appropriate use of medicines and pharmacoeconomics. Clinical pharmacist researchers produce, distribute and apply new information that contributes to improving health and quality of life. Thus, it is ensured that many of the drug treatment errors that occur after inappropriate therapeutic decisions are made at the point of prescribing are prevented In this investigation, the effects of clinical pharmacists on respiratory would be investigated. This research area will cover lower respiratory tract infections and chronic lung disease exacerbations with ICD-10 codes J05, J9-22, J40-47, J69, J85 -J86. In this study, two groups, control and intervention groups, were identified. In the control group; There will be no intervention done by the Clinical Pharmacist. Hospital stay, antimicrobial suitability, microbial resistance development, antimicrobial induced nephrotoxicity, infection-related mortality, pharmacoeconomic evaluation, re-hospitalization within 30 days after discharged, medication reconciliation report will be created, patients will be monitored for the detection and management of drug-related problems will be recorded in both control and intervention groups. In the intervention group; recommendations will be given to the physicians by the Clinical Pharmacist on the selection of antibiotics, drug suitability, dosage and route of administration advice, and determination of drug-related problems related to drugs used simultaneously.

Conditions

Pneumonia; COPD Asthma; COPD Exacerbation

Keywords

Clinical Pharmacist; Drug-Related Problems; Chest-Diseases; Cognitive Pharmacy Services

Outcome Measures

Primary Outcomes (3)

• Acceptance rate of suggested intervention

  Acceptance rate of suggested intervention

  Immediately after the intervention

• Length of hospital stay

  Length of hospital stay

  Immediately after the discharge of the participant

• 30-day readmission

  Readmission within 30 day

  30 day after the intervention/after the discharge of the each participant

Study Arms (2)

Control Group

NO INTERVENTION

In the control group; No intervention will be made by the investigators in this group. The participant will take standard treatment. Participant's length of stay in hospital, suitability of antibiotics used, development of microbial resistance, Antibiotic related nephrotoxicity due to infection, mortality data due to infection will be recorded, hospitalization will be questioned within 30 days after the patient is discharged, and a drug consensus report will be created, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be made. Evaluations will be recorded, but the investigators will take no action.

Intervention Group

EXPERIMENTAL

In the intervention group; The participant will take standard treatment and the clinical pharmacist services such as drug reconciliation by the investigators, medication review (Identification of drug-related problems, detection of possible unsuitable drugs), quality of life measurement, antibiotic selection, drug suitability, dose and route of administration advice, and concomitant medications are included. Suggestions will be made by the investigators to physicians about the solution to drug-related problems. Participants' length of hospital stay, suitability of antibiotics, development of microbial resistance, antibiotic-related nephrotoxicity due to infection, and mortality numbers due to infection will be recorded, hospitalization will be questioned within 30 days after discharge. The investigators will create a drug consensus report, drug-related problems will be determined, and a pharmacoeconomic evaluation of all possible outcomes will be accomplished by investigators.

Behavioral: Intervention groups

Interventions

Intervention groups BEHAVIORAL

The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.

Intervention Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Having any of the J05, J9-22, J40-47, J69, J85-J86 diagnoses specified in the ICD-10 guideline,
• Patients hospitalized due to respiratory tract infection and using antibiotic drugs,
• Being 18 years or older,
• Having signed the written consent form to participate in the study.

You may not qualify if:

• The consent form is not approved,
• Not having the necessary cognitive abilities,
• Being under the age of 18

Sponsors & Collaborators

• Bezmialem Vakif University: lead
• Marmara University: collaborator

Study Sites (1)

Bezmialem Vakif University

Istanbul, 34093, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pneumonia

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Mesut Sancar, Prof. Dr.

  Marmara University, Department of Clinical pharmacy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Asistant Professor

Study Record Dates

• First Submitted: September 26, 2022
• First Posted: October 3, 2022
• Study Start: June 30, 2020
• Primary Completion: January 31, 2021
• Study Completion: December 31, 2021
• Last Updated: October 5, 2022

Record last verified: 2022-10

Locations

TU (1)